Advertisement
Home »

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.

Jan 16, 2023

ABOUT THE CONTRIBUTORS

  • Omar Alhalabi

    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

    Jonathan Thouvenin

    Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France.

    Institut de Cancérologie Strasbourg Europe (ICANS/HUS), Strasbourg, France.

    Sylvie Négrier

    Université Lyon I, Centre Léon Bérard, Lyon, France.

    Yann-Alexandre Vano

    Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre-Université de Paris, Paris, France.

    Luca Campedel

    AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

    Elshad Hasanov

    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

    Ziad Bakouny

    Dana-Farber Cancer Institute, Boston, MA, USA.

    Brigham and Women’s Hospital, Boston, MA, USA.

    Andrew W Hahn

    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

    Mehmet Asim Bilen

    Winship Cancer Institute of Emory University, Atlanta, GA, USA.

    Pavlos Msaouel

    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

    Toni K Choueiri

    Dana-Farber Cancer Institute, Boston, MA, USA.

    Srinivas R Viswanathan

    Dana-Farber Cancer Institute, Boston, MA, USA.

    Kanishka Sircar

    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

    Laurence Albiges

    Institut Gustave Roussy, Villejuif, France.

    Gabriel G Malouf

    Institut de Cancérologie Strasbourg Europe (ICANS/HUS), Strasbourg, France.

    Nizar M Tannir

    The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement